Antibody-drug conjugates in colorectal cancer: advances in targeted delivery and personalized oncology.

Colorectal cancer remains among the most prevalent gastrointestinal malignancies worldwide, imposing a substantial clinical burden and highlighting the urgent need for precision and personalized treatment strategies. Conventional drug delivery approaches are limited by low selectivity, restricted bioavailability, and systemic toxicity, thereby limiting therapeutic efficacy. Antibody-drug conjugates, as advanced delivery plat-forms, have the advantages of highly specific antibody recognition, versatile cytotoxic payloads, and continuously evolving linker technologies. This combination provides novel opportunities to increase efficacy, reduce toxicity, and enable individualized precision therapy. Recent advances have demonstrated the potential of ADCs in CRC, yet challenges such as resistance, toxicity, and clinical translation persist. Multidisciplinary efforts among the pharmaceutical industry and molecular biology and clinical medicine fields will be essential to accelerate the development of more precise and personalized CRC therapies. This review summarizes the current research progress on ADCs as a treatment option for CRC, discusses innovations in delivery system design, examines the key challenges of personalization, and highlights future directions to better integrate ADCs into effective treatment paradigms.

• Publication year

  2026

• Venue

  Frontiers in Bioengineering and Biotechnology

• Publication date

  2026-02-12

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.3389/fbioe.2026.1756741PMID 41768137PMCID PMC12936049
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Dual-payload ADCs move into first oncology clinical trials

  2025cited by this paper
• Targeting HER2 in Metastatic Colorectal Cancer: Current Therapies, Biomarker Refinement, and Emerging Strategies

  2025cited by this paper
• Cancer treatment and survivorship statistics, 2025

  2025cited by this paper
• Combined therapy with DR5-targeting antibody-drug conjugate and CDK inhibitors as a strategy for advanced colorectal cancer

  2025cited by this paper
• Cost-effectiveness of sacituzumab govitecan for hormone receptor-positive human epidermal growth factor receptor 2-negative metastatic breast cancer based on the EVER-132-002 trial in China

  2025cited by this paper
• Overcoming multidrug resistance in gastrointestinal cancers with a CDH17-targeted ADC conjugated to a DNA topoisomerase inhibitor

  2025cited by this paper
• Precemtabart tocentecan, an anti-CEACAM5 antibody–drug conjugate, in metastatic colorectal cancer: a phase 1 trial

  2025cited by this paper
• Generation and characterization of 7DC-DM1: a non-cleavable CD47-targeting antibody-drug conjugates with antitumor effects.

  2025cited by this paper
• Broad-Spectrum Efficacy of CEACAM6-Targeted Antibody–Drug Conjugate with BET Protein Degrader in Colorectal, Lung, and Breast Cancer Mouse Models

  2025cited by this paper
• Antibody–Drug Conjugates (ADCs): current and future biopharmaceuticals

  2025cited by this paper
• SHR-A1811, a novel anti-HER2 antibody–drug conjugate with optimal drug-to-antibody ratio, efficient tumor killing potency, and favorable safety profiles

  2025cited by this paper
• Treatment-related adverse events of antibody drug-conjugates in clinical trials

  2025cited by this paper
• Cost-effectiveness analysis of trastuzumab emtansine for second-line treatment of HER2+ advanced breast cancer in Singapore

  2025cited by this paper
• Efficacy and safety of neoadjuvant SHR-A1811 with or without pyrotinib in women with locally advanced or early HER2-positive breast cancer: a randomized, open-label, phase 2 trial.

  2025cited by this paper
• RC48 Induces Senescence in HER2-Expressing Colon Cancer Cells by Activating the CDKN1A-RB-E2F1 Pathway.

  2025cited by this paper
• DB-1310, a HER3-targeting antibody-drug conjugate, has synergistic anti-tumor activity with trastuzumab in HER2- and HER3-expressing breast cancer

  2025cited by this paper
• Precemtabart tocentecan (M9140), an anti-CEACAM5 ADC with exatecan payload, in patients with metastatic colorectal cancer (mCRC): Results from the dose optimization of the phase 1 PROCEADE CRC-01 study.

  2025cited by this paper
• Preparation and anti-tumor ability evaluation of anti-PD-L1 conjugated curcumin in colon cancer.

  2025cited by this paper
• Nano particle loaded EZH2 inhibitors: Increased efficiency and reduced toxicity for malignant solid tumors

  2025cited by this paper
• Exploring the next generation of antibody–drug conjugates

  2024cited by this paper
• Antibody-drug conjugates: prospects for the next generation.

  2024cited by this paper
• A New Age of Drug Delivery: A Comparative Perspective of Ferritin-Drug Conjugates (FDCs) and Antibody-Drug Conjugates (ADCs).

  2024cited by this paper
• Future AI Will Most Likely Predict Antibody-Drug Conjugate Response in Oncology: A Review and Expert Opinion

  2024cited by this paper
• Antibody-Drug Conjugates: The Toxicities and Adverse Effects That Emergency Physicians Must Know.

  2024cited by this paper
• Recent Technological and Intellectual Property Trends in Antibody–Drug Conjugate Research

  2024cited by this paper
• Exploring the Role of Target Expression in Treatment Efficacy of Antibody–Drug Conjugates (ADCs) in Solid Cancers: A Comprehensive Review

  2024cited by this paper
• LRG1 promotes metastatic colorectal cancer growth through HER3 signaling.

  2024cited by this paper
• Fexofenadine-loaded chitosan coated solid lipid nanoparticles (SLNs): A potential oral therapy for ulcerative colitis.

  2024cited by this paper
• Safety and efficacy of antibody-drug conjugates plus immunotherapy in solid tumours: A systematic review and meta-analysis.

  2024cited by this paper
• SHR-A1811 (antibody-drug conjugate) in advanced HER2-mutant non-small cell lung cancer: a multicenter, open-label, phase 1/2 study

  2024cited by this paper
• Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial.

  2024cited by this paper
• RN486, a Bruton's Tyrosine Kinase inhibitor, antagonizes multidrug resistance in ABCG2-overexpressing cancer cells

  2024cited by this paper
• The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors

  2024cited by this paper
• Azobenzene-based Linker Strategy for Selective Activation of Antibody-Drug Conjugates.

  2024cited by this paper
• Chemotoxicity and Associated Risk Factors in Colorectal Cancer: A Systematic Review and Meta-Analysis

  2024cited by this paper
• Immunotherapy for colorectal cancer

  2024cited by this paper
• Delivery of a BET protein degrader via a CEACAM6-targeted antibody–drug conjugate inhibits tumour growth in pancreatic cancer models

  2024cited by this paper
• Antibody-Drug Conjugates Targeting the EGFR Ligand Epiregulin Elicit Robust Anti-Tumor Activity in Colorectal Cancer.

  2024cited by this paper
• Clinical Pharmacology of the Antibody–Drug Conjugate Enfortumab Vedotin in Advanced Urothelial Carcinoma and Other Malignant Solid Tumors

  2024cited by this paper
• Synergistic antitumor activity between HER2 antibody-drug conjugate and chemotherapy for treating advanced colorectal cancer

  2024cited by this paper
• Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2–Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2–Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial

  2024cited by this paper
• Antibody–Drug Conjugates—Evolution and Perspectives

  2024cited by this paper
• Antibody-Drug Conjugate Overview: a State-of-the-art Manufacturing Process and Control Strategy

  2024cited by this paper
• Nanotechnology-based delivery systems to overcome drug resistance in cancer

  2024cited by this paper
• Influence of antibody–drug conjugate cleavability, drug-to-antibody ratio, and free payload concentration on systemic toxicities: A systematic review and meta-analysis

  2024cited by this paper
• Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy

  2024cited by this paper
• HER2-low gastric cancer: is the subgroup targetable?

  2024cited by this paper
• Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-C014): a phase 1b/2 dose-escalation and dose-expansion study.

  2024cited by this paper
• Anti-Claudin-2 Antibody-Drug Conjugates for the Treatment of Colorectal Cancer Liver Metastasis.

  2024cited by this paper
• Abstract 2362: Preclinical efficacy and safety of M9140, a novel antibody-drug conjugate (ADC) with topoisomerase 1 (TOP1) inhibitor payload targeting carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)-expressing colorectal tumors

  2024cited by this paper
• DB-1310, an ADC comprised of a novel anti-HER3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of HER3-positive solid tumors

  2024cited by this paper
• The tumor immune microenvironment remodeling and response to HER2‐targeted therapy in HER2‐positive advanced gastric cancer

  2023cited by this paper
• Antibody–drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry

  2023cited by this paper
• Abstract HER2-17: HER2-17 Novel Quantitative HER2 Assay for Determining Dynamic HER2 Expression in the HER2 IHC 0 “Ultra-Low” Setting: Implications for Precision Therapy in HER2- Breast Cancer

  2023cited by this paper
• Therapeutic efficacy of a MMAE-based anti-DR5 drug conjugate Oba01 in preclinical models of pancreatic cancer

  2023cited by this paper
• A phase I, first-in-human study of TAK-164, an antibody–drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C

  2023cited by this paper
• Abstract P6-04-03: Computational pathology based HER2 expression quantification in HER2-low breast cancer

  2023cited by this paper
• Improving the response to oxaliplatin by targeting chemotherapy-induced CLDN1 in resistant metastatic colorectal cancer cells

  2023cited by this paper
• Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3–Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3–Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Trial

  2023cited by this paper
• A HER2‐targeted Antibody‐Drug Conjugate, RC48‐ADC, Exerted Promising Antitumor Efficacy and Safety with Intravesical Instillation in Preclinical Models of Bladder Cancer

  2023cited by this paper
• Payload diversification: a key step in the development of antibody–drug conjugates

  2023cited by this paper
• A HER2-targeting antibody-MMAE conjugate RC48 sensitizes immunotherapy in HER2-positive colon cancer by triggering the cGAS-STING pathway

  2023cited by this paper
• HER-3 surface expression increases in advanced colorectal cancer representing a potential therapeutic target

  2023cited by this paper
• PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer

  2023cited by this paper
• Preparation of an Ultrahigh-DAR PDL1 monoclonal antibody-polymeric-SN38 conjugate for precise colon cancer therapy.

  2023cited by this paper
• Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2–Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials

  2023cited by this paper
• Antibody-exatecan conjugates with a novel self-immolative moiety overcome resistance in colon and lung cancer.

  2023cited by this paper
• Wnt/β-catenin pathway is a key signaling pathway to trastuzumab resistance in gastric cancer cells

  2023cited by this paper
• A comprehensive review of key factors affecting the efficacy of antibody drug conjugate.

  2023cited by this paper
• Antibody–drug conjugates come of age in oncology

  2023cited by this paper
• Mechanisms of Resistance to Antibody-Drug Conjugates

  2023cited by this paper
• Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer

  2023cited by this paper
• Tumor neoantigens: Novel strategies for application of cancer immunotherapy

  2023cited by this paper
• The genomic and immune landscapes of gastric cancer and their correlations with HER2 amplification and PD‐L1 expression

  2023cited by this paper
• 189O A phase II study of patritumab deruxtecan (HER3-DXd), in patients (pts) with advanced breast cancer (ABC), with biomarker analysis to characterize response to therapy (ICARUS-BREAST01)

  2023cited by this paper
• Safety and efficacy of CRISPR-based non-viral PD1 locus specifically integrated anti-CD19 CAR-T cells in patients with relapsed or refractory Non-Hodgkin's lymphoma: a first-in-human phase I study

  2023cited by this paper
• AMT-562, a Novel HER3-targeting Antibody–Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors

  2023cited by this paper
• DOG1 as a novel antibody-drug conjugate target for the treatment of multiple gastrointestinal tumors and liver metastasis

  2023cited by this paper
• Radioimmunotherapy in colorectal cancer treatment: present and future

  2023cited by this paper
• An antibody–drug conjugate targeting GPR56 demonstrates efficacy in preclinical models of colorectal cancer

  2023cited by this paper
• An amino acid transporter subunit as an antibody–drug conjugate target in colorectal cancer

  2023cited by this paper
• Preclinical Evaluation of IMGC936, a Next Generation Maytansinoid-based Antibody-drug Conjugate Targeting ADAM9-expressing Tumors.

  2022cited by this paper
• Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer

  2022cited by this paper
• Antibody drug conjugate: the “biological missile” for targeted cancer therapy

  2022cited by this paper
• Evaluation of Safety of Treatment With Anti–Epidermal Growth Factor Receptor Antibody Drug Conjugate MRG003 in Patients With Advanced Solid Tumors

  2022cited by this paper
• Transient Inhibition of Trastuzumab-Tumor Binding to Overcome the "Binding-Site Barrier" and Improve the Efficacy of a Trastuzumab-Gelonin Immunotoxin.

  2022cited by this paper
• Immunogenic cell stress and death

  2022cited by this paper
• Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate

  2022cited by this paper
• HER2 targeted therapy in colorectal cancer: New horizons.

  2022cited by this paper
• Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies

  2022cited by this paper
• Pathophysiological and pharmacological considerations to improve the design and application of antibody-drug conjugates.

  2022cited by this paper
• Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastoma

  2022cited by this paper
• ERBB Signaling Pathway in Cancer Stem Cells.

  2022cited by this paper
• The Dawn of the Antibody-Drug Conjugates Era: How T-DM1 Reinvented the Future of Chemotherapy for Solid Tumors.

  2022cited by this paper
• CUB Domain-Containing Protein 1 (CDCP1) is a rational target for the development of imaging tracers and antibody-drug conjugates for cancer detection and therapy

  2022cited by this paper
• Peptide-Drug Conjugates: A New Hope for Cancer Management

  2022cited by this paper
• Non-internalising antibody-drug conjugates.

  2022cited by this paper
• The therapeutic window of antibody drug conjugates: A dogma in need of revision.

  2022cited by this paper
• Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: First-in-human dose-escalation study.

  2022cited by this paper
• Treatment‐related adverse events of antibody–drug conjugates in clinical trials: A systematic review and meta‐analysis

  2022cited by this paper

• No citing papers are available for this paper.